Clinical trials: Advanced Hepatocellular Carcinoma
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Trial name
- NCT07493044
- Testing
- Super CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.
- Trial name
- Wondercel-UWD3 (NCT06653023)
- Testing
- Universal CAR-T cells injection for treating HCC and NSCLC, MMF Immunosuppression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Advanced Hepatocellular Carcinoma
Itacitinib in Advanced Hepatocellular Carcinoma
This research will assess the effects of Itacitinib as a second line treatment for patients with advanced inflammatory hepatocellular carcinoma (HCC), a type of liver cancer.
- Trial name
- JAKaL (NCT04358185)
- Testing
- Itacitinib
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Imperial College London
Gastric Cancer, Hepatocellular Carcinoma
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy.
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Advanced Solid Tumor
- Trial name
- NCT04118114
- Testing
- PRL3-zumab
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- National Cancer Centre, Singapore
Advanced Unresectable Hepatocellular Carcinoma
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma.
- Trial name
- NCT07478302
- Testing
- SHR-2524 Injection, Bevacizumab Injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Unresectable Hepatocellular Carcinoma
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine…
- Trial name
- NCT07175441
- Testing
- RBS2418, STRIDE (durvalumab + tremelimumab)
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- Riboscience, LLC.
Advanced Hepatocellular Carcinoma (HCC)
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
- Trial name
- HCC-IM-1 (NCT07147101)
- Testing
- Sintilimab, Bevacizumab Biosimilar, Camrelizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01899261
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Montefiore Medical Center
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
This phase Ib trial investigates the side effects of durvalumab and tremelimumab after radioembolization (radiation particles against liver tumors) and to see how well they work in treating patients with liver cancer that cannot…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04605731
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT05257590
- Testing
- Nivolumab Injection [Opdivo], CVM-1118
- Where
- 5 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- TaiRx, Inc.
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
This phase II trial tests how well giving Y-90 radioembolization, durvalumab, tremelimumab and zanzalintinib works for the treatment of hepatocellular carcinoma that cannot be removed by surgery (unresectable) and that has spread…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07511504
- Testing
- Angiogram, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer
TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to attack the cancer.
- Conditions
- Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT03680508
- Testing
- TSR-022 and TSR-042
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Hawaii
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better.
- Trial name
- RADIANT (NCT07312292)
- Testing
- Angiotensin II (Giapreza®), Yttrium-90 radioembolization
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Niek Wijnen
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech